Healthy Participants
Conditions
Keywords
BMS-986308, Congestive heart failure (CHF), Diuretics, Diuretic resistance, Fluid overload, Furosemide, Persistent congestion
Brief summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986308 compared to placebo in healthy participants.
Interventions
DRUGBMS-986308
Specified dose on specified days
OTHERPlacebo (for BMS-986308)
Specified dose on specified days
DRUGFurosemide
Specified dose on specified days
Sponsors
Bristol-Myers Squibb
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Must be in good health, as determined by no clinically significant deviations from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations * Must have a body mass index (BMI) of 18.0 kg/m\^2 to 32.0 kg/m\^2, inclusive, at screening. BMI = weight (kg)/height (m)\^2 * Must have normal renal function at screening (and study admission) as evidenced by an estimated glomerular filtration rate (eGFR) ≥ 80 mL/min/1.73 m\^2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula
Exclusion criteria
* Any significant acute or chronic medical illness * Presence or need for urinary catheterization, urinary tract abnormality, or disorder interfering with urination * History of tinnitus or hearing impairment, including deafness * History or risks factors for Torsade de Pointes and Long QT syndrome (such as electrolyte imbalances, etc) * History of, or active, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection * Consumption of caffeine or xanthine-containing food or beverages within 72 hours prior to study treatment administration * Use of any prescription drugs or over-the-counter (OTC) acid controllers within 4 weeks prior to study treatment administration except those medications cleared by the Medical Monitor * Use of any other drugs, including OTC medications within 1 week and herbal preparations, within 2 weeks prior to study treatment administration except those medications cleared by the Medical Monitor * Use of diuretics (loop diuretics, thiazide diuretics, potassium-sparing diuretics \[spironolactone, amiloride\]), oral calcium, potassium or magnesium supplements (including multi-vitamins) or use of non-steroidal anti-inflammatory drugs within 72 hours of the first study treatment * Use of concomitant medications that are strong inhibitors or inducers of cytochrome CYP3A4 or OATP administered within 2 weeks prior to study treatment administration and throughout the study * Consumption of any nutrients known to modulate cytochrome P450 (CYP) enzymes activity (eg, grapefruit, or grapefruit juice,pomelo juice, star fruit, or Seville \[blood\] orange products) within 14 days prior to first administration of study treatment * Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population of healthy volunteers * History of allergy to furosemide, sulfonamides, other loop diuretics (furosemide cohort only), BMS-986308 or related compounds, components of the suspension or solution, including hydroxypropylmethylcellulose Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of clinically significant changes in physical examination findings | Up to 19 days | Part B |
| Incidence of death | Up to 19 days | Part B |
| Incidence of adverse events (AEs) leading to discontinuation | Up to 19 days | Part B |
| Incidence of clinically significant changes in clinical laboratory results: Hematology tests | Up to 19 days | Part B |
| Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests | Up to 19 days | Part B |
| Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests | Up to 19 days | Part B |
| Incidence of clinically significant changes in vital signs: Respiratory rate | Up to 19 days | Part B |
| Incidence of clinically significant changes in vital signs: Supine blood pressure | Up to 19 days | Part B |
| Incidence of clinically significant changes in vital signs: Heart rate | Up to 19 days | Part B |
| Incidence of clinically significant changes in vital signs: Orthostatic hypotension measurements performed as per clinical research unit's standard operating procedure | Up to 19 days | Part B |
| Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval | Up to 19 days | Part B PR interval is the time from the onset of the P wave to the start of the QRS complex |
| Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS | Up to 19 days | Part B QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization |
| Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval | Up to 19 days | Part B The QT interval is the time from the start of the Q wave to the end of the T wave |
| Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF | Up to 19 days | Part B QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave |
| Incidence of clinically significant changes in cardiac telemetry | Up to 19 days | Part B |
| Incidence of Adverse Events (AEs) | Up to 19 days | Part B |
| Incidence of serious adverse events (SAEs) | Up to 19 days | Part B |
Other
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events (AEs) | Up to 14 days | Part A |
| Incidence of serious adverse events (SAEs) | Up to 72 days | Part A |
| Incidence of death | Up to 72 days | Part A |
| Incidence of adverse events (AEs) leading to discontinuation | Up to 72 days | Part A |
| Incidence of clinically significant changes in vital signs: Respiratory rate | Up to 14 days | Part A |
| Incidence of clinically significant changes in vital signs: Supine blood pressure | Up to 14 days | Part A |
| Incidence of clinically significant changes in vital signs: Heart rate | Up to 14 days | Part A |
| Incidence of clinically significant changes in vital signs: Orthostatic hypotension measurements performed as per clinical research unit's standard operating procedure | Up to 3 days | Part A |
| Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS | Up to 14 days | Part A QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization |
| Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval | Up to 14 days | Part A The QT interval is the time from the start of the Q wave to the end of the T wave |
| Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF | Up to 14 days | Part A QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave |
| Incidence of clinically significant changes in cardiac telemetry | Up to 3 days | Part A |
| Incidence of clinically significant changes in physical examination findings | Up to 14 days | Part A |
| Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval | Up to 14 days | Part A PR interval is the time from the onset of the P wave to the start of the QRS complex |
Countries
United States
Outcome results
None listed